223 related articles for article (PubMed ID: 26406386)
1. Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
Franchi F; Rollini F; Park Y; Angiolillo DJ
Future Cardiol; 2015 Sep; 11(5):547-64. PubMed ID: 26406386
[TBL] [Abstract][Full Text] [Related]
2. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
3. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
Moon JY; Franchi F; Rollini F; Angiolillo DJ
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
[TBL] [Abstract][Full Text] [Related]
4. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
[TBL] [Abstract][Full Text] [Related]
5. Vorapaxar in the secondary prevention of atherothrombosis.
Tantry US; Liu F; Chen G; Gurbel PA
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
[TBL] [Abstract][Full Text] [Related]
6. Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.
Cho JR; Rollini F; Franchi F; Ferrante E; Angiolillo DJ
Vasc Health Risk Manag; 2014; 10():177-88. PubMed ID: 24729713
[TBL] [Abstract][Full Text] [Related]
7. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.
Gryka RJ; Buckley LF; Anderson SM
Drugs R D; 2017 Mar; 17(1):65-72. PubMed ID: 28063023
[TBL] [Abstract][Full Text] [Related]
8. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.
Moschonas IC; Goudevenos JA; Tselepis AD
Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282
[TBL] [Abstract][Full Text] [Related]
9. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.
Leonardi S; Tricoci P; Becker RC
Drugs; 2010 Oct; 70(14):1771-83. PubMed ID: 20836572
[TBL] [Abstract][Full Text] [Related]
10. Platelet protease-activated receptor antagonism in cardiovascular medicine.
Wiisanen ME; Moliterno DJ
Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
[TBL] [Abstract][Full Text] [Related]
11. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
Ungar L; Rodriguez F; Mahaffey KW
Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E;
Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854
[TBL] [Abstract][Full Text] [Related]
13. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
Gurbel PA; Jeong YH; Tantry US
Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
[TBL] [Abstract][Full Text] [Related]
14. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
Cavender MA; Scirica BM; Bonaca MP; Angiolillo DJ; Dalby AJ; Dellborg M; Morais J; Murphy SA; Ophuis TO; Tendera M; Braunwald E; Morrow DA
Circulation; 2015 Mar; 131(12):1047-53. PubMed ID: 25681464
[TBL] [Abstract][Full Text] [Related]
15. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
Lam S; Tran T
Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
[TBL] [Abstract][Full Text] [Related]
16. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
Duerschmied D; Bode C
Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
[TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action and clinical development of platelet thrombin receptor antagonists.
Ueno M; Ferreiro JL; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1191-200. PubMed ID: 20670195
[TBL] [Abstract][Full Text] [Related]
19. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
Cheng JW
Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
[TBL] [Abstract][Full Text] [Related]
20. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
Cai TQ; Wickham LA; Sitko G; Michener MS; Raubertas R; Handt L; Chintala M; Seiffert D; Forrest M
Eur J Pharmacol; 2015 Jul; 758():107-14. PubMed ID: 25857224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
